Abstract
Antipsychotics are widely used for the treatment of behavioral and psychological symptoms of dementia (BPSD). Concerns have been raised in the literature over the safety of antipsychotics, with suggestions of an increased risk of mortality. The objective of this study was to determine the all-cause mortality risk associated with antipsychotic use among Alzheimer’s disease (AD) patients. A new-user study was conducted in a multicentric prospective cohort, composed of 534 community-dwelling mild-to-moderate AD patients recruited in 16 French memory centers. A survival analysis using a Cox proportional hazards model assessed hazard ratios (HRs) for death according to either first or second generation antipsychotic use (time-varying variable). Among the 534 patients, 102 new users were identified throughout the 3.5 year-follow-up period and 113 deaths occurred. The main antipsychotics used were risperidone and tiapride. Unadjusted and sociodemographic-adjusted (age, gender, center) analyses suggested an increased risk of death with antipsychotic use (HR: 1.84; 95% CI: [1.09-3.09] and HR: 1.93; 95% CI: [1.15-3.25]) respectively). However, antipsychotic use did not appear to be an independent predictive factor of death when dementia severity (cognitive status) was accounted for during fully adjusted multivariate analyses (HR: 1.12; 95% CI: [0.59-2.12]). Antipsychotic use may be associated with an increased risk of mortality, but to a lesser extent than several other factors which were found to be significant predictors of mortality (age, male gender, cognitive score, recent hospitalisation, medical aid). To date, antipsychotic risks outweigh their benefits in BPSD for which non-pharmacological approaches remain the first-line strategy and should be privileged.
Keywords: Antipsychotic agents, mortality, Alzheimer disease, dementia, cohort studies, antipsychotics, psychiatric disorders, neuroendocrine disease.
Current Alzheimer Research
Title:Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity
Volume: 9 Issue: 9
Author(s): Virginie Gardette, Maryse Lapeyre-Mestre, Nicola Coley, Christelle Cantet, Jean-Louis Montastruc, Bruno Vellas and Sandrine Andrieu
Affiliation:
Keywords: Antipsychotic agents, mortality, Alzheimer disease, dementia, cohort studies, antipsychotics, psychiatric disorders, neuroendocrine disease.
Abstract: Antipsychotics are widely used for the treatment of behavioral and psychological symptoms of dementia (BPSD). Concerns have been raised in the literature over the safety of antipsychotics, with suggestions of an increased risk of mortality. The objective of this study was to determine the all-cause mortality risk associated with antipsychotic use among Alzheimer’s disease (AD) patients. A new-user study was conducted in a multicentric prospective cohort, composed of 534 community-dwelling mild-to-moderate AD patients recruited in 16 French memory centers. A survival analysis using a Cox proportional hazards model assessed hazard ratios (HRs) for death according to either first or second generation antipsychotic use (time-varying variable). Among the 534 patients, 102 new users were identified throughout the 3.5 year-follow-up period and 113 deaths occurred. The main antipsychotics used were risperidone and tiapride. Unadjusted and sociodemographic-adjusted (age, gender, center) analyses suggested an increased risk of death with antipsychotic use (HR: 1.84; 95% CI: [1.09-3.09] and HR: 1.93; 95% CI: [1.15-3.25]) respectively). However, antipsychotic use did not appear to be an independent predictive factor of death when dementia severity (cognitive status) was accounted for during fully adjusted multivariate analyses (HR: 1.12; 95% CI: [0.59-2.12]). Antipsychotic use may be associated with an increased risk of mortality, but to a lesser extent than several other factors which were found to be significant predictors of mortality (age, male gender, cognitive score, recent hospitalisation, medical aid). To date, antipsychotic risks outweigh their benefits in BPSD for which non-pharmacological approaches remain the first-line strategy and should be privileged.
Export Options
About this article
Cite this article as:
Gardette Virginie, Lapeyre-Mestre Maryse, Coley Nicola, Cantet Christelle, Montastruc Jean-Louis, Vellas Bruno and Andrieu Sandrine, Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer’s Disease Patients: Evidence for a Role of Dementia Severity, Current Alzheimer Research 2012; 9 (9) . https://dx.doi.org/10.2174/156720512803569037
DOI https://dx.doi.org/10.2174/156720512803569037 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research HIV and Substance Abuse: A Commentary
Current HIV Research The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Origin and Expansion of Trinucleotide Repeats and Neurological Disorders
Current Genomics Preface:
CNS & Neurological Disorders - Drug Targets Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Threshold-Independent Meta-Analysis of Alzheimer`s Disease Transcriptomes shows Progressive Changes in Hippocampal Functions, Epigenetics and microRNA Regulation
Current Alzheimer Research A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research Mortality and Treatment Costs have a Great Impact on the Cost- Effectiveness of Disease Modifying Treatment in Alzheimer’s Disease - A Simulation Study
Current Alzheimer Research DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Editorial [Celebrating the Fifth Year Anniversary of Current Alzheimer Research(Guest Editor: Debomoy K. Lahiri)]
Current Alzheimer Research Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis?
Current Genomics From Presenilinase to γ-Secretase, Cleave to Capacitate
Current Alzheimer Research Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Current Pharmaceutical Design Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Overview and Findings from the Religious Orders Study
Current Alzheimer Research Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets